4//SEC Filing
Myles David C. 4
Accession 0001831216-26-000003
CIK 0001750284other
Filed
Jan 13, 7:00 PM ET
Accepted
Jan 14, 9:30 PM ET
Size
21.2 KB
Accession
0001831216-26-000003
Insider Transaction Report
Form 4
Myles David C.
CH. DISCOV. & NON-CLIN DEV OFF
Transactions
- Sale
Common Stock
[F1][F2]2026-01-12$28.34/sh−10,000$283,400→ 144,846 total(indirect: See Footnote) - Exercise/Conversion
Common Stock
[F3]2026-01-13$4.87/sh+50,000$243,500→ 592,761 total - Sale
Common Stock
[F4]2026-01-13$27.60/sh−49,800$1,374,480→ 542,961 total - Sale
Common Stock
2026-01-13$28.49/sh−200$5,698→ 542,761 total - Exercise/Conversion
Common Stock
2026-01-14$4.87/sh+50,000$243,500→ 592,761 total - Sale
Common Stock
[F5]2026-01-14$28.60/sh−14,997$428,914→ 577,764 total - Sale
Common Stock
[F6]2026-01-14$28.99/sh−35,003$1,014,737→ 542,761 total - Exercise/Conversion
Stock Option (Right to Buy)
[F8]2026-01-13−50,000→ 100,000 totalExercise: $4.87Exp: 2033-01-31→ Common Stock (50,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F9]2026-01-14−50,000→ 50,000 totalExercise: $4.87Exp: 2033-01-31→ Common Stock (50,000 underlying)
Holdings
- 12,831(indirect: See Footnote)
Common Stock
[F7]
Footnotes (9)
- [F1]The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F2]The shares are held by Myles Properties Inc., of which the Reporting Person is President.
- [F3]On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4.
- [F4]The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.
- [F5]The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F6]The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F7]The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
- [F8]25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
- [F9]25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Signature
/s/ Shane Kovacs, Attorney-in-Fact|2026-01-14
Documents
Issuer
Olema Pharmaceuticals, Inc.
CIK 0001750284
Entity typeother
Related Parties
1- filerCIK 0001831216
Filing Metadata
- Form type
- 4
- Filed
- Jan 13, 7:00 PM ET
- Accepted
- Jan 14, 9:30 PM ET
- Size
- 21.2 KB